"A 53-year-old female ex-smoker (10 pack-years) presented with progressive dyspnea in February 2014. Her performance status was 1. She was diagnosed with stage IV lung adenocarcinoma with lung, lymph node, and bone involvement. Molecular testing revealed an ALK receptor tyrosine kinase (ALK) translocation with no other concomitant alterations. Our case describes a patient with ALK-rearranged NSCLC who developed pulmonary toxicity on brigatinib that recurred after exposure to lorlatinib at early onset. READ ARTICLE
Journal of Thoracic Oncology DOI:10.1016/j.jtho.2019.06.013
Authors: Xavier Monzonís, Edurne Arriola"